Jun Yan

Dr. Jun Yan


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
BWBingyang Wang
Bingyang Wang
CLCong Li
Cong Li
JGJiatong Gu
Jiatong Gu
XWXiaojie Wang
Xiaojie Wang
MXMingjuan Xun
Mingjuan Xun
JYJun Yan
Jun Yan
Glioblastoma (GBM), the most aggressive and lethal subtype of glioma, remains therapeutically intractable despite advances in surgical and chemo-radiotherapy interventions. The highly immunosuppressive tumor microenvironment (TME) contributes significantly to treatment resistance and tumor recurrence. Among the predominant immune constituents, glioma-associated microglia and macrophages (GAMs) constitute a major cellular compartment, exerting profound influence on tumor progression, immune evasion, angiogenesis, and therapeutic response. These myeloid populations, derived from both yolk sac–origin microglia and bone marrow–derived macrophages, exhibit remarkable functional plasticity and are actively recruited, polarized, and reprogrammed by tumor-intrinsic and environmental cues. Recent studies have elucidated a range of molecular pathways, including chemokine signaling, metabolic reprogramming, and epigenetic modulation, that govern GAM behavior and sustain their tumor-supportive phenotype. Therapeutic strategies targeting GAM recruitment, depletion, or functional re-education toward an anti-tumor state are emerging as promising adjuncts to conventional and immune-based therapies. This review comprehensively explores the ontogeny, regulatory networks, and pathological roles of GAMs in GBM, with particular emphasis on novel immunotherapeutic approaches, including CSF-1R blockade, nanoparticle-mediated reprogramming, and oncolytic virotherapy. A deeper understanding of GAM–TME interactions will be critical to overcoming immunotherapy resistance and advancing precision immunomodulation in GBM.

19 November 2024 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
ZCZiwen Cao
Ziwen Cao
XLXing Liu
Xing Liu
JYJun Yan
Jun Yan
Introduction: The CD16A protein encoding gene FcγRIIIa (FCGR3A) and its potential ligand Fibrinogen-like protein 2 (FGL2) are involved in various cell physiological activities on the extracellular surface. Aberrant expression of these genes has been linked to tumorigenesis.Methods: To assess the prognostic significance of FCGR3A and FGL2 transcription expression in glioma and explore their roles in glioma initiation and progression, we utilized multiple online databases, including TCGA, GEPIA, CGGA, cBioPortal, TISCH, LinkedOmics, Ivy Glioblastoma Atlas Project, and Human Protein Atlas.Results: Our analysis revealed that FCGR3A and FGL2 expression was significantly correlated with clinical variables such as age, tumor type, WHO grade, histology, IDH-1 mutation, and 1p19q status. A strong correlation was also observed between the transcriptional expression levels of FCGR3A and FGL2. High expression of both genes predicted poor prognosis in primary and recurrent glioma patients, particularly those with lower grade gliomas. Cox regression analysis further confirmed that elevated expression of FCGR3A and FGL2 were independent prognostic factors for shorter overall survival in glioma patients. Gene co-expression network analysis suggested that FCGR3A, FGL2, and their co-expressed genes were involved in inflammatory activities and tumor-related signaling pathways. Additionally, tissue microarrays from glioma patients at Tiantan Hospital showed significantly higher FCGR3A protein expression in high-grade gliomas compared to low-grade gliomas.Discussion: In conclusion, our findings suggest that FCGR3A and FGL2 could serve as promising prognostic biomarkers and potential therapeutic targets for glioma patients.

Verified
Journal Article
Open access
PDF file
CYCaiyuan Yu
Caiyuan Yu
XMXun Mingjuan
Xun Mingjuan
FYFei Yu
Fei Yu
HLHengyu Li
Hengyu Li
YLYing Liu
Ying Liu
JYJun Yan
Jun Yan
Glioma is the most common primary malignant intracranial tumor with limited treatment options and a dismal prognosis. This study aimed to develop a robust gene expression-based prognostic signature for GBM using the Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) datasets. Using WGCNA and LASSO algorithms, we identified four MHC-related genes (TNFSF14, MXRA5, FCGR2B, and TNFRSF9) as prognostic biomarkers for glioma. A risk model based on these genes effectively stratified patients into high- and low-risk groups with distinct survival outcomes across TCGA and CGGA cohorts. This signature correlated with immune pathways and glioma progression mechanisms, showing strong associations with immune function and tumor microenvironment infiltration patterns. The risk score reflected tumor microenvironment remodeling, suggesting its prognostic relevance. We further propose I-BET-762 and Enzastaurin as potential therapeutic candidates for glioma. In conclusion, the four-gene signature we identified and the corresponding risk score model constructed from it provide valuable tools for the prognosis prediction of glioblastoma multiforme (GBM) and may guide personalized treatment strategies. The least absolute shrinkage and selection operator (LASSO) risk score has demonstrated significant prognostic evaluation utility in clinical GBM patients, bringing potential implications for patient stratification and the optimization of treatment regimens.

16 June 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SXShaohua Xu
Shaohua Xu
XNXuedong Niu
Xuedong Niu
CZChanglin Zhang
Changlin Zhang
QLQianyuan Li
Qianyuan Li
CLChunhua Luo
Chunhua Luo
JYJun Yan
Jun Yan
Increasing evidence has highlighted the biological significance of 5-methylcytosine (5mC) DNA modification in regulating tumorigenesis and cancer progression. However, the potential roles of the 5mC modification in HCC are still unknown. A consensus clustering algorithm was performed to determine 5mC modification patterns and establish a 5mC-related gene signature in HCC. Weighted gene co‑expression network analysis (WGCNA) integrated with machine learning approaches (LASSO, RF, and SVM‑RFE) was applied to identify candidate biomarkers, and a 5mC risk score model was subsequently constructed. The concordance index (C‑index), decision curve analysis (DCA), and ROC curve were employed to evaluate the performance of the nomogram. Two distinct 5mC modification patterns were identified, with cluster B exhibiting worse prognosis and enrichment of cell cycle and metabolic pathways. Using integrated WGCNA and machine learning, we constructed a three-gene (DNMT1, SPATS2, MCM6) risk score model that effectively stratified patients into high- and low-risk groups with significantly different overall survival. The risk score demonstrated robust prognostic performance across independent cohorts and was an independent prognostic factor. High risk scores correlated with advanced stage, higher tumor mutational burden, distinct immune microenvironment features, and increased sensitivity to multiple chemotherapeutic and targeted agents. A nomogram incorporating the risk score and clinicopathological features showed acceptable predictive accuracy and clinical net benefit. Experimental validation confirmed upregulation of DNMT1 and SPATS2 in HCC tissues, and their knockdown suppressed HCC cell proliferation, migration, and invasion. The 5mC risk model demonstrates clinical applicability and net benefit in terms of prognostic stratification, immunophenotype characterization, and prediction of drug therapy response in HCC patients, providing a useful tool for precision oncology.

28 December 2024
Verified
Dataset
Closed access
PDF file
XMXun Mingjuan
Xun Mingjuan
LHLin Han
Lin Han
YCYu Caiyuan
Yu Caiyuan
PBPang Bo
Pang Bo
WYWang Yongzhi
Wang Yongzhi
JYJun Yan
Jun Yan
Spinal cord gliomas are commonly malignant tumors of the spinal cord, leading to a high rate of disability. However, uniform treatment guidelines and comprehensive data on spinal cord gliomas remain limited due to the lack of suitable preclinical animal models. Developing a simple and reproducible animal model has become essential for advancing basic and translational research. A murine model is ideal, as the murine spinal cord shares structural similarities with the human spinal cord. This protocol describes the generation of a reproducible murine model of spinal cord glioma by directly injecting tumor cells into the intervertebral space using the spinous process of the seventh cervical vertebra as a guide. Compared to other methods, this approach is more effective and convenient, involving a smaller incision, reduced invasiveness and blood loss, faster recovery, and more stable tumor formation. This model is expected to advance the understanding of disease mechanisms, optimize surgical strategies, and support the development of therapeutic drugs for spinal cord gliomas.

27 December 2024 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
XMXun Mingjuan
Xun Mingjuan
LHLin Han
Lin Han
YCYu Caiyuan
Yu Caiyuan
PBPang Bo
Pang Bo
WYWang Yongzhi
Wang Yongzhi
JYJun Yan
Jun Yan
Spinal cord gliomas are commonly malignant tumors of the spinal cord, leading to a high rate of disability. However, uniform treatment guidelines and comprehensive data on spinal cord gliomas remain limited due to the lack of suitable preclinical animal models. Developing a simple and reproducible animal model has become essential for advancing basic and translational research. A murine model is ideal, as the murine spinal cord shares structural similarities with the human spinal cord. This protocol describes the generation of a reproducible murine model of spinal cord glioma by directly injecting tumor cells into the intervertebral space using the spinous process of the seventh cervical vertebra as a guide. Compared to other methods, this approach is more effective and convenient, involving a smaller incision, reduced invasiveness and blood loss, faster recovery, and more stable tumor formation. This model is expected to advance the understanding of disease mechanisms, optimize surgical strategies, and support the development of therapeutic drugs for spinal cord gliomas.